Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Leave It To Beaver: Rozerem DTC Campaign Boosts New Rx Share

This article was originally published in The Pink Sheet Daily

Executive Summary

Takeda sleep aid’s new Rx share has grown more than 50% since campaign began.

You may also be interested in...



Rozerem DTC Ad Suggests Insomnia Drug Is Indicated In Children - FDA

Takeda's direct-to-consumer TV ad for the insomnia drug Rozerem (ramelteon) fails to disclose the drug's indication, does not include information related to side effects and suggests through "back to school"-themed images and statements that the drug is indicated in children, FDA says in a warning letter issued to the company March 5 and posted online March 8

Rozerem DTC Ad Suggests Insomnia Drug Is Indicated In Children – FDA

Agency issues an "untitled" letter to Takeda citing the 10-second TV spot.

Rozerem DTC Ad Suggests Insomnia Drug Is Indicated In Children – FDA

Agency issues an "untitled" letter to Takeda citing the 10-second TV spot.

Related Content

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel